Our attorneys have filed a mass tort lawsuit on behalf of patients who took the blood thinner Xarelto (rivaroxaban) and suffered critical bleeding events. Pharmaceutical companies, such as the makers of Xarelto, have a duty to ensure that their drugs are reasonably protected for use - and failure to complete so may be grounds for compensation. Our lawyers are functioning tough to get these hurt by the drug the compensation they may be entitled to.
Whilst bleeding can be a common complication related with anticoagulants, it has been alleged that Xarelto is a lot more hazardous than standard blood thinners simply because no antidote exists to reverse its blood-thinning effects. This implies that, inside the event of an emergency, sufferers might be at danger for irreversible bleeding troubles, which includes life-threatening internal and gastrointestinal hemorrhaging.
Should you or even a loved a single suffered a severe bleeding event after taking Xarelto, you might have legal recourse. For more info, make contact with us today to have your case reviewed, cost-free of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are seeking compensation from Bayer and Janssen for past and future health-related bills, lost wages, discomfort and suffering and, in instances of death, funeral costs. Furthermore, they're seeking punitive damages, which are generally awarded to punish the defendant and deter other firms from acting similarly.
Why Are Lawsuits Becoming Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is harmful and defective. The plaintiffs claim that, unlike standard anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Due to the fact of this, the lawsuits claim, doctors have no effective indicates of stopping Xarelto users from bleeding within please click the next page occasion of an emergency. Plaintiffs in the lawsuits allege serious and fatal injuries, like cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior in the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and health-related staff were not properly made aware of methods to stabilize and treat a Xarelto user in the event of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to severe bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing harmful clotting.
Visit this page for more data on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys inside the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.